Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-748-5975
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.35 million
Profitability
Miscellaneous
Employees115
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. The firm earned $3.52 million during the quarter, compared to analyst estimates of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative return on equity of 101.60%. View Dova Pharmaceuticals' Earnings History.
When is Dova Pharmaceuticals' next earnings date?
What price target have analysts set for DOVA?
6 equities research analysts have issued 12 month target prices for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 6.0%. View Analyst Price Targets for Dova Pharmaceuticals.
What is the consensus analysts' recommendation for Dova Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.
Has Dova Pharmaceuticals been receiving favorable news coverage?
News headlines about DOVA stock have trended negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Dova Pharmaceuticals.
Are investors shorting Dova Pharmaceuticals?
Dova Pharmaceuticals saw a drop in short interest in September. As of September 15th, there was short interest totalling 1,770,000 shares, a drop of 16.9% from the August 15th total of 2,130,000 shares. Based on an average daily trading volume, of 419,500 shares, the days-to-cover ratio is currently 4.2 days. Currently, 13.6% of the company's shares are short sold. View Dova Pharmaceuticals' Current Options Chain.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Reata Pharmaceuticals (RETA), Taro Pharmaceutical Industries (TARO), Allakos (ALLK), Alkermes (ALKS), Global Blood Therapeutics (GBT), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of Dova Pharmaceuticals own?
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Dr. David S. Zaccardelli, Pres & CEO (Age 54)
- Mr. Mark W. Hahn, CFO & Sec. (Age 56)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)
- Mr. Jason Levine, VP of Marketing
- Mr. Ilija Zlatar, Head of U.S. Sales
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $28.11.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $809.62 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.
What is Dova Pharmaceuticals' official website?
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
